Citations

  1. Helmick CG, Felson DT, Lawrence RC, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part I. Arthritis Rheum 2008;58: 15-25.
    https://onlinelibrary.wiley.com/doi/full/10.1002/art.23177   
     

  2. Vivino, F. B. (2017). Sjogren’s syndrome: Clinical aspects. 2017;182: 48–54.
    https://doi.org/10.1016/j.clim.2017.04.005
     

  3. Brito-zerón, P, Theander, E, Baldini, C. et al, Quartuccio, L, Bootsma, H, … Fox, R. Early diagnosis of primary Sjögren’ s syndrome : EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016; 12(2): 137–156.
    https://www.ncbi.nlm.nih.gov/pubmed/26691952
     

  4. Criswell, LA, Shiboski, C H, Shiboski, SC, Labetoulle, M, Lietman,TM, Rasmussen, A, … Mariette, X. (2016).  American College of Rheumatology / European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome.Arthritis Rheum 2017; 69(1): 35-45.
    https://onlinelibrary.wiley.com/doi/full/10.1002/art.39859
     

  5. Bournia V-K, Vlachoyiannopoulous PG. Subgroups of Sjogren syndrome patients according to serologic profiles. Journal of Autoimmunity 2012;39: 15-26.
    https://www.ncbi.nlm.nih.gov/pubmed/22575069
     

  6. Didlier K, Bloko L, et al. Autoantibodies Associated with Connective Tissue Diseases: What Meaning for Clinicians? Front Immunol 2018;9: 1-20.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879136/

7. Carsons S (1998) The New Sjogren’s Syndrome Handbook Carsons,S, Harris E (Eds.)  New York: The Medical Workup of Sjogren's Syndrome.  Oxford University Press.
 

8.  Demarchi J, Papasidero S, Medina,MA, et al.Primary Sjogren’s syndrome: Extraglandular manifestations and hydroxychloroquine therapy.Clin Rheum 2017;36(11): 2455-2460.

https://www.ncbi.nlm.nih.gov/pubmed/28913747
 

9. Sandhu P, Ambrus Jr. JL. Novel Autoantibodies in Sjogren’s Syndrome. J Immunol Clin Res 2017; 4(1): 1034.

https://www.ncbi.nlm.nih.gov/pubmed/23123440
 

10. Ng, WF (ed). (2016) Sjogren's Syndrome. Oxford, UK: Oxford University Press

 

11. Baldini C, Ferro F, Elefante E. Bombardieri S. Biomarkers for Sjogren’s Syndrome. Biomark Med 2018;12(3): 275-286.

https://www.ncbi.nlm.nih.gov/pubmed/29460647

 

12.Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman S, Dorner T…Vitali C. on behalf of EULAR Sjogren Syndrome Task Force.Characterization of systemic disease in primary Sjogren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015;54: 2230-2238.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281074/

13. Sheikh S, Shaw-Stiffel T. The gastrointestinal manifestations of Sjogren’s syndrome. Am J Gastroenterol 1995; 90(1): 9-14.
 https://www.ncbi.nlm.nih.gov/pubmed/7801957
 

14. Fox RI. Advances in understanding, diagnosing and treating Sjogren syndrome.

https://www.medscape.com/viewarticle/848782

 

15. Beckman KA, Luchs J, Milner MS, Ambrus JL Jr. The potential role for early biomarker testing as part of a modern, multidisciplinary approach to Sjogren’s syndrome diagnosis. Adv Ther 2017;34(4): 799-812.

https://core.ac.uk/display/81617896 (open access)

 

16. Ferro F, Vagelli R, Bruni C, Cafaro G, Marcucci E, Bartoloni E, Baldini C. One year in review 2016: Sjogren’s syndrome. Clin Exp Rheumatol 2016;34: 161-171.
https://www.clinexprheumatol.org/article.asp?a=10452
 

 

17. Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown R, Morgan P, Bombardieri S…Barone F on behalf of the Sjogren’s histopathology workshop group, EULAR Sjogren’s syndrome study group. Standardization of labial salivary gland histopathology in clinical trials in primary Sjogren’s Syndrome. Ann Rheum Dis 2017;76: 1161-1168.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530351/
 

18. Fox, PC. Is a lip biopsy 100 % accurate? The Moisture Seekers, March 2018.(p.17)

http://www.sjogrens.org/files/tms/tms2008-03.pdf

 

19. Serin G, Karabulut G, Kabasakal Y, Kandiloglu G, Akalin T. The importance of minor salivary gland biopsy in Sjogren syndrome diagnosis and the clinicopathological correlation. Turk Patoloji Derg. 2016;32(2):65-9.
http://www.turkjpath.org/text.php3?doi=10.5146/tjpath.2015.01346

 

20. Reksten TR, Jonsson MV. Sjogren’s syndrome: An update on epidemiology and current insights on pathophysiology. Oromaxillofacial Surg Clin N Am 2014;26(1): 1-12
https://www.ncbi.nlm.nih.gov/pubmed/24287189

 

21. Akpek EK, Bunya VY, Saldanha IF.Ocular manifestations of primary Sjogren’s: what you don’t know might surprise you. Sjogren’s Quarterly; 13 (3) Summer 2018.
https://www.ncbi.nlm.nih.gov/pubmed/30681523

 

22. Hammitt KM, Naegeli AN, van den Broek, RWM, Birt, JA. Patient burden of Sjogren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity. Rmdopen2017; 3(2)-e000443  https://rmdopen.bmj.com/content/3/2/e000443
 

23. Rasmussen A, Radfar L, Lewis D, Grundahl K, Stone DU, Kaufman CE, … Scofiled RH. Previous diagnosis of Sjogren’s syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology 2016 Jul;55(7): 1195-201.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281033/

 

24. Brito-Zeron, P, Ramos-Casals M.Systemic Sjogrens: More than a sicca disease.

https://www.the-rheumatologist.org/article/systemic-sjgrens-more-than-a-sicca-disease/ 
 

25. Sjogren’s Syndrome Foundation.Breakthrough Goal survey results 2016. Polaris Marketing Research; 2016.

 

26. Ng, Wan-Fai.Primary Sjogren’s syndrome: Too dry and too tired. Rheumatology 2010;49: 844-853.
 https://www.ncbi.nlm.nih.gov/pubmed/20147445
 

27. Segal G, Bowman S et al. Primary Sjogren’s syndrome: health experiences and predictors of health quality among patients in the United States.Health Qual Life Outcomes. 2009 ;7:46 

https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-7-46 
 

28. Dusenbery, M.  Doing Harm. 2018, New York: HarperCollins
 

29. http://simpletasks.org/wp-content/uploads/2018/08/Rheumatic-Disease-Report-Card-US.pdf
 

30. Brito-Zeron P, Ramos-Casals M, et al. Predicting adverse outcomes in primary Sjogren’s syndrome: identification of prognostic factors. Rheumatology 2007;46:1359-1362
https://www.ncbi.nlm.nih.gov/pubmed/17569749

32. McCoy SS, Baer AN.Neurological Complications of Sjogren’s Syndrome: Diagnosis and Management. Curr Treatm Opt Rheumatol 2017; 3(4):275-288
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322693/pdf/nihms-986304.pdf

 

 

33. Goodman BP, Crepeau A, Dhawan PS, Khoury JA, Harris L. Spectrum of autonomic nervous system impairment in Sjogren syndrome. The Neurologist 2017;22:127-130.
https://www.ncbi.nlm.nih.gov/pubmed/28644253

34. Bunya, VY, Fernandez, KG et al. Survey of ophthalmologists regarding practice patterns for dry eye and Sjogren syndrome.  Eye & Contact Lens 2018;44:S196-S201.
https://www.ncbi.nlm.nih.gov/pubmed/29369232
 

35. Akpek EK, Mathews, P et al. Ocular and systemic morbidity in a longitudinal cohort of Sjogren’s syndrome  Ophthalmology 2015;122:56-61
https://www.ncbi.nlm.nih.gov/pubmed/25178806

36. Kabasakal Y, Kitapcioglu G et al.  Criteria sets for primary Sjogren’s syndrome are not adequate for those presenting with extraglandular organ involvements as their dominant clinical features.  Rheumatol Int (2017) 37:675–684
https://www.ncbi.nlm.nih.gov/pubmed/28289872
 

37. Seror R, Bowman SJ, Brito-Zeron P…Mariette X, on behalf of the EULAR Sjogren’s Task Force.EULAR Sjogren’s Syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015;1:e000022.
https://www.researchgate.net/publication/282530767_EULAR_Sjogren's_syndrome_disease_activity_index_ESSDAI_a_user_guide
https://rmdopen.bmj.com/content/1/1/e000022       (Open access)

38. Ramos-Casals M, Brito-Zeron P… Kostov B on behalf of the SS Study Group and Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine.  Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).  Rheumatology 2014;53:321-331
https://www.ncbi.nlm.nih.gov/pubmed/24162151

 

39. Flament T, Bigot A Chaigne et al. Pulmonary manifestations of Sjogren’s syndrome. European Respiratory Review 2016; 25: 110-123   
https://err.ersjournals.com/content/25/140/110

 

40. Alpek  EK, Bunya VY, Saldanha IJ.  Sjogren’s Syndrome: More than just dry eye. Cornea 2019 Jan 22.  
https://www.ncbi.nlm.nih.gov/pubmed/30681523

41.  Tiensvoll AB, Goransson LG. High headache-related disability in patients with systemic lupus erythematosus and primary Sjogren’s syndrome.  Eur J Neurol 2014;21(8):1124-30
https://tinyurl.com/y5hpjra2

 

42. Brito-Zeron P, Baldini C, Bootsma H…Ramos-Casals M. Sjogren’ Syndrome. 2016 Nature Reviews Disease Primers. 2016;2:1-20.

https://www.ncbi.nlm.nih.gov/pubmed/27383445
 

43. Sutcliffe N, Stoll T et al.Functional disability and end-organ damage in patients with systemic lupus and Sjogren’s syndrome. J Rheumatol 1998;25(1):63-68  

 https://www.ncbi.nlm.nih.gov/pubmed/9458204
                      

44. Strömbeck B, Ekdahl C, Manthorpe R, et al. Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36.  Scand J Rheumatol. 2000; 29(1):20–281.
https://www.ncbi.nlm.nih.gov/pubmed/10722254

 

45. Mirouse A, Seror, Vicaut E… Mekinian A on behalf of Club Rheumatismes Inflammation and SNFMI. Arthritis in primary Sjogren’s syndrome: Characteristics, outcome, and treatment from a French multicenter retrospective study. Autoimmun Rev. 2019 Jan;18(1):9-14
https://www.ncbi.nlm.nih.gov/pubmed/30408585

 

46. Wallace, DJ. (2012). Sjogren’s Syndrome Foundation.Oxford, UK: Oxford University Press.

 

47. Both T, Dalm VASH, van Hagen PM, van Daele PLA. Reviewing primary Sjogren’s syndrome:beyond the dryness- From pathophysiology to diagnosis and treatment.  Int J Med Sci 2017; (14): 191-200.
http://www.medsci.org/v14p0191.htm   

48.Tjensvoll AB.(2016). Headache in systemic lupus erythematosus and primary Sjogren’s syndrome.

(Doctoral dissertation, University of Bergen)
 

49. Ng W-F, Stangroom AJ, Davidson A, Wilton K, Mitchell S, Newton JL. Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure.  Q J Med 2012; 105:1191-1199.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508582/  Open Access

 

50. Newton, JL, Frith J, Powell … Ng, WF on behalf of the UK primary Sjogren’s syndrome registry. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren’s Syndrome. Ann Rheum Dis 2012;71: 1973-1979

https://www.ncbi.nlm.nih.gov/pubmed/22562982   Open Access

 

51.  Koh JH, Kwok SK, Lee Jet al.  Autonomic dysfunction in primary Sjogren’s syndrome: a prospective cohort analysis of 154 Korean patients.  Korean J Intern Med 2017;32:165-173
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214725/pdf/kjim-2015-219.pdf

 

52. Mori K, Iijima M, Koike H…Sobue G.The wide spectrum of clinical manifestations in Sjogren syndrome-associated neuropathy. Brain 2005; 128: 2518-2534.
 https://www.ncbi.nlm.nih.gov/pubmed/16049042        

 

53.  Kovacs L, Paprika, D, Takacs R,. Pokorny G. Cardiovascular autonomic dysfunction in primary Sjogren’s syndrome. Rheumatology 2004;43(1):95-99

https://www.ncbi.nlm.nih.gov/pubmed/12949253
 

54. Stojan G, Baer AN, Danoff SK. Pulmonary manifestations of Sjogren’s syndrome. Curr Allergy Asthma Rep 2013; 13(4); 354-360.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393654/pdf/nihms-674901.pdf

 

55. Ocon Aj, Messer ZR, Medow MS, Stewart JM. Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome. Clin Sci 2012: 122 (5):227-238.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368269/

56.  Carsons SE, Vivino FB, Parke A… Mandel S.Treatment guidelines for Rheumatologic manifestations of Sjogren’s:Use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res 2017:  Apr;69(4):517-527.  https://www.ncbi.nlm.nih.gov/pubmed/27390247
 

57.Price EH, Rauz S, Tappuni AR… Bowman, SJ; on behalf of the British Society for Rheumatology Standards, Guideline and Audit Working Group. The British Society for Rheumatology guideline for management of adults with primary Sjogren’s syndrome.Rheumatology. 2017: Oct 1;56(10):1828 
https://www.ncbi.nlm.nih.gov/pubmed/28957572

58. Price EJ, Baer AN. How to treat Sjogren’s syndrome. Rheumatology, 2019, Feb. 15. (epub ahead of print)
https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/key363/5321166
 

59. Thomas Jr., DE. The Lupus Encyclopedia, a Comprehensive Guide for Patients and Families. 2014.  Johns Hopkins University Press.

60. Hernandez-Molina G, Valim V...Catalan-Pellet A.  Do antimalarials protect against damage accrual in primary Sjogren's syndrome? Results from a Latin-American retrospective cohort. Clin Exp Rheumatol 2018;36 (Suppl.112):S182-S185   https://www.clinexprheumatol.org/article.asp?a=12439   (Open Access)

61.  Brito-Zeron P, Kostov B, Solans R... Ramos-Casals M. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016;75:348-355.

https://www.ncbi.nlm.nih.gov/pubmed/25433020

 

62. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum,  2000 Apr; 29 (5):296-304

https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+evolution+and+morbidity+and+mortality+of+primary+Sjogren%27s

63. Retamozo S, Acar- Denizli N, Rasmussen A...Brito-Zeron, P. Systemic manifestations of primary Sjogren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large, international, multi-ethnic cohort of patients. Clin Exp Rheumatol 2019; 37 (Suppl. 118):S97-S106.

https://www.clinexprheumatol.org/article.asp?a=14220

64. James JA, Guthridge JM, Chen H...St. Clair E.W. Unique Sjogren's syndrome patient subsets defined by molecular features. Rheumatology 2019; Sep 8 (Epub ahead of print)

https://www.ncbi.nlm.nih.gov/pubmed/31497844

65.  Imgenberg-Kreuz J, Almlof JC, Leonard D,...Nordmark G. Shared and unique patterns of DNA methylation in systemic lupus erythematosus and primary Sjogren's Syndrome. Front Immunol 2019;10:1686.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688520/

66. Nocturne G, Mariette X.  B cells in the pathogenesis of primary Sjogren syndrome. Nat Rev Rheumatol 2018 Mar;14(34):133-145

https://www.ncbi.nlm.nih.gov/pubmed/29416129

67. Bombardieri M, BaldiniC ...Baer AN. Highlights of the 14th International Symposium on Sjogren's Syndrome. Clin Exp Rheumatol 2018;36 (Suppl. 112): S3-S13:675-684.  

https://www.clinexprheumatol.org/article.asp?a=13089   (Open Access)

 

68. Varan O, Babaoglu H, Goker B.  Associations between depressive disorders and inflammatory rheumatic diseases. Curr Top Med Chem 2018;18(16):1395-1401

https://www.ncbi.nlm.nih.gov/pubmed/29766809

69. Akpek EK, Bunya VY, Saldanha IJ. Sjogren's syndrome: more than just dry eye. Cornea 2019;00:1-4.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Akpek+EK+Bunya+VY%2C+Saldanha

70.Konty E, Lewandowska-Poluch, A, Chmielinska M, Olesinkska M. Subgroups of Sjogren's syndrome patients categorised by serological profiles: clinical and immunological characteristics.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330679/

71. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases. Nat Rev Rheumatol 2014; 11: 86-97

https://www.nature.com/articles/nrrheum.2014.193

72. Harris VM, Scofield RH, Sivils KL. Genetics in Sjogren's syndrome: where are we and where will we go. Clin Exp Rheumatol 2019; 37 (Suppl. 118): S234-S239.

https://www.ncbi.nlm.nih.gov/pubmed/31464674

 

73. Tsirves GK, Voulgari PV, Pelechas E, Asimakopoulos AD, Drosos AA.  Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolayrngo. 2019;276(9):2419-2426

https://www.ncbi.nlm.nih.gov/pubmed/31175453

 

74. Applbaum E, Lichtbroun A.  Novel Sjogren's autoantibodies found in fibromyalgia patients with sicca and/or xerostomia. Autoimmun Rev 2019 Feb 18(2):199-202 .

https://www.ncbi.nlm.nih.gov/pubmed/30572137

 

75.  Elliott G, Spence AR, Czurzoj-Shulman N, Abenhaim HA. Effect of Sjogren's syndrome on maternal and neonatal outcomes of pregnancy.  J Perinatal Med 2019;47(6): 637-642

76. Yazisiz V, Gocer M, Ebrasan F...Terzioglu ME. Survival analysis of patients with Sjogren's syndrome in Turkey: a tertiary hospital-based study. Clin Rheumatol 2019 Sept. 25 (Epub ahead of print)

https://www.ncbi.nlm.nih.gov/pubmed/31555987
 

77.Aggarwal R, Ringold S, Khanna D...Feldman BM. Distinctions between diagnostic and classification criteria. Arthritis Care Res 2015;67(7):891-897

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482786/

78. Alunno A, Bartoloni E...Gerli R. Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjogren's syndrome. Clin Exp Rheumatol 2018;36 (Suppl.112): S210-S214. https://www.clinexprheumatol.org/article.asp?a=12955

 

79.Vivino F, Bunya V, Massaro-Giordano G, AmbrusJr, JL. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol 203 (2019) 81-121.

 

https://www.ncbi.nlm.nih.gov/pubmed/31022578

80. Maciel G, Servioli L, Nannini C...Cornec D. Hospitalisation rates among patients with primary Sjogren's syndrome: a population-based study, 1995-2016. RMD Open 2018;4:e000575.

https://rmdopen.bmj.com/content/4/1/e000575

81. Abrol E, Gonzelez-Pulido C, Praena-Fernandez HN, Isenberg DA. A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience. Clin Med 2014;14(2):157-164.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4953287/

82. Walsh N, Wilson, FP, Caputo D. Sjogren's carries heavy disease burden. April 26, 2013. BSR meeting coverage. (Presentation based on citation 81, with additional commentary).

https://www.medpagetoday.org/meetingcoverage/bsr/38713?vpass=1 

83. Al-Ezzi M, Khan K, Tappuni AR. Is the taste acuity affected by oral dryness in primary Sjogren's syndrome patients?  Oral Dis Dec 19 (Epub ahead of print) 

https://www.ncbi.nlm.nih.gov/pubmed/31856365

84. Trevisani VFM, Pasoto SG, Fernandes MLMS...Valim V. Recommendations from the Brazilian society of rheumatology for the diagnosis of Sjogren's syndrome (Part I): glandular manifestations (systematic review).  Advances in Rheumatology 2019; 59:58 OPen access electronic. 

https://www.ncbi.nlm.nih.gov/pubmed/31852541

85. Moreira I, Teixeira, Silva AM, Santos E. Frequent involvement of the central nervous system in primary Sjogren syndrome. Rheumatol Int 2015;53:289-294

www.ncbi.nlm.nih.gov/pubmed/25056402

 

86. Manzo C, Martinez-Suarez E, Kechids M, Isetta M, Serra-Mestres K. Cognitive function in primary Sjogren's syndrome: A systematic review. Brain Sci 2019;9(4):85  (Epub, open access)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523842/

 

87. Birnbaum, J. Clinical peripheral nervous system manifestations of Sjogren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis and therapeutic strategies.  Neurologist 2010;16(5):287-297.

https://www.ncbi.nlm.nih.gov/pubmed/20827117

88. Omdal R, Mallegren SI, Norheim KB. Pain and fatigue in primary Sjogren's syndrome. Rheumatology, 2019. (epub pages 1-8).

https://www.ncbi.nlm.nih.gov/pubmed/30815693

89. Sambataro G, Ferro F, Orlandi M..Matucci CM. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjogren's syndrome: A systematic review from the Italian Society of  Rheumatology. 2019 Dec 14 (Epub ahead of print)

https://doi.org/10.1016/j.autrev.2019.102447

 

90. Guisado-Vasco P, Silva M, Duarte-Millán MA, Sambataro G, Bertolazzi C, et al. (2019) Quantitative assessment of interstitial lung disease in Sjögren’s syndrome. PLOS ONE 14(11): e0224772.

https://doi.org/10.1371/journal.pone.0224772

91. Mengshoel AM, Norheim KB, Omdal R.  Primary Sjogren's syndrome: fatigue is an ever-present, fluctuating, and uncontrollable lack of energy.  Arthritis Care Res 2014;66:1227-32.  

https://onlinelibrary.wiley.com/doi/full/10.1002/acr.22263      (Open access)

92. Brito-Zeron P, Acar Denizli N, Ng WF...Trevisani VFM.  Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjogren's syndrome. Rheumatology 2019;0:1-10 (E pub ahead of print)

https://www.ncbi.nlm.nih.gov/pubmed/31873754

93. Brito-Zeron P, Acra-Denizli, N, Zeher M...Ramos-Casals M. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjogren Project Consortium. Ann Rheum Dis 2017;76:1042-50. 

https://ard.bmj.com/content/76/6/1042

94. Mccormick N, Marra CA... Avina-Zubietta JA.  Excess productivity costs of systemic lupus erythematosus, systemic sclerosis and Sjogren's syndrome: a general population-based study. Arthritis Care Res 2019;71(1):142-154.

https://www.ncbi.nlm.nih.gov/pubmed/29648677

95. Radfar L, Kleiner DE, Fox PC, Pillemer SR.  Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 2002; 47(5):520-524.

https://onlinelibrary.wiley.com/doi/full/10.1002/art.10668  (open access)

 

96. Cafaro G, Croia C, Argyopoulou OD...Bartoloni E. One year in review 2019: Sjogren's syndrome.  Clin Exp Rheumatol  2019;37 (Suppl.118): S3-S15).

 

https://www.clinexprheumatol.org/article.asp?a=14480  (open access)

97. Vasaitis L, Nordmark G, Theander E...Baecklund E. Comparison of patients with and without pre-existing lymphoma at diagnosis of Sjogren's syndrome. Scand J Rheumatol 2019;48(3):207-212.

https://www.ncbi.nlm.nih.gov/pubmed/30422723

98. Living with Sjogren’s Survey 2016: Summary of major findings.

https://www.sjogrens.org/sites/default/files/inline-files/LivingwithSjogrens-8.5x11Bifold-2020.pdf

99. Park EH, Strand V…Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.  Arth Res Ther 2019;21:61.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377714/ (Open access)

100. Segal B, Thomas W…Moser K.  Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren’s syndrome. Arthritis Rheum 2008;59 (12):1780-7.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106978/ ( Open access)

101.  Segal BM, Pogatchnik B…Moser KL. Primary Sjogren’s syndrome: cognitive symptoms, mood and cognitive performance.  Acta Neurol Scand 2012;125(4):272-8

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188671/ (Open access)

102  Uffmann, M., Kiener, H. P., Bankier, A. A., Baldt, M. M., Zontsich, T., & Herold, C. J. (2001). Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests. Journal of thoracic imaging, 16(4), 282–289. https://doi.org/10.1097/00005382-200110000-00009

https://pubmed.ncbi.nlm.nih.gov/11685093/

103. Bartoloni E, Baldini C…Gerli R. Cardiovascular disease risk burden in primary Sjogren’s syndrome: results of a population-based multicenter cohort study.  J Intern Med 2015;278: 185-192.
 https://www.ncbi.nlm.nih.gov/pubmed/25582881   (Open access)

104. Bartoloni E, Alunno A…Gerli R. Subclinical atherosclerosis in primary Sjogren’s syndrome: Does inflammation matter? Front Immunol 2019 Apr 17;10:817
https://www.ncbi.nlm.nih.gov/pubmed/31110500  (Open access)

105. Avina-Zubieta JA, Jansz M, Sayre EC, Choi HK. The risk of deep venous thrombosis and pulmonary embolism in primary Sjogren syndrome: A general population-based study. J Rheumatol 2017 Aug;44(8):1184-1189.
https://www.ncbi.nlm.nih.gov/pubmed/28298559 (Open access)

106. Tsai YD, Chien WC, Tsai SH...Wang JC. Increased risk of aortic aneurysm and dissection in patients with Sjogren’s syndrome: a nationwide population-based cohort study in Taiwan.  BMJ Open 2018;8:e022326
https://bmjopen.bmj.com/content/8/9/e022326 (Open access)

107. Brom M, Moyano S..Soriano ER. Incidence of cancer in a cohort of patients with primary Sjogren syndrome in Argentina.   Rheumatol Int 2019;39(10):1697-1702.

https://www.ncbi.nlm.nih.gov/pubmed/31471716

108. Chang CC, Lin TM…Chen JH. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Ann Med 2018;50(1): 83-90.

https://www.ncbi.nlm.nih.gov/pubmed/29224375

109. Hou TY, Hsu HC…Chen JH.   Higher risk of dementia in primary Sjogren’s syndrome.  Ann Clin Transl Neurol 2019;6(4):633-641.   
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.737  ( Open access)

110.  Anaya JM, Restrepo-Jimenez P…Mantilla RD.  Sjogren’s syndrome and thyroid disease: two sides of the same coin. Clin Rev Allergy Immunol 2019 Jun;56(3):362-374.

https://www.ncbi.nlm.nih.gov/pubmed/30187363

111. Bartoloni E, Bistoni O…Gerli R. Celiac disease prevalence is increased in primary Sjogren’s syndrome and diffuse systemic sclerosis: lessons from a large multi—center study.  J Clin Med 2019;8(4):1-14.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517955/  (Open access)

112. Parreau S, Jacques J... Fauchais AL. Abdominal symptoms during Sjogren's syndrome: a prospective study. Epub ahead of print. Jan. 8, 2020.

https://www.biorxiv.org/content/10.1101/2020.01.08.898379v1.full.pdf  (Open access)

113. Brito-Zeron P, Retamozo S, Ramos-Casals M. Phenotyping Sjogren's syndrome: towards a personalised management of the disease. Clin Exp Rheumatol 2018;36 (Suppl.112): S198-S209.

https://www.clinexprheumatol.org/article.asp?a=12950    (Open access)

114. Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjogren's syndrome: why? Clin Exp Rheumatol 2018; 36(Suppl.112): S27-S28.

https://www.clinexprheumatol.org/article.asp?a=12868   (Open access)

115.Bjerrum K, Prause JU.  Primary Sjogren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 1990;8(3): 283-288.

http://europepmc.org/article/MED/2379343

116  Flores-Chavez A, Kostov B ... Ramos-Casals M. Severe, life-threatening phenotype of primary Sjogrens syndrome: clinical characterisation and outcomes in 1580 patients (GEWAS-SS Registry).  Clin Exp Rheumatol 2018;36  (Suppl 112): S121-S129.

https://www.clinexprheumatol.org/abstract.asp?a=12884    (Open access)

117. Baldini C, Pepe P... Bombardieri. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2013;53: 839-844.

https://pubmed.ncbi.nlm.nih.gov/24369420

118. Gottenberg JE, Seror R...Mariette X. Serum levels of Beta2-microblobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PloS One 2013;8: 1-6

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663789/   (Open access)

119. Brito-Zeron P, Acar-Denizli N...Ramos-Casals M, Sjogren Big Data Consortium.  How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project).

Clin Exp Rheumatol 2018;36 Suppl. 112): S102-S112.

https://www.clinexprheumatol.org/article.asp?a=12899    (Open access)

120. Brunetta E, Shiffer D...Furlan R. Autonomic abnormalities in patients with primary Sjogren's syndrome- preliminary results.  Front Physiol 2019; 10: 1-13.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736624/pdf/fphys-10-01104.pdf    (Open access)

121. Quartuccio L, Gandolfo S...De Vita S.  Articular and peripheral nervous system involvement are linked to the long-term outcome in primary Sjogren's syndrome: the relevance of single organ manifestations rather than a composite score as predictors.  Front Immunol 2019;10: 1527

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637305/    (Open access)

122.  Kollert F, Fisher BA.  Equal rights in autoimmunity: is Sjogren’s syndrome ever “secondary”? Rheumatology 2020:0:1-8  (epub ahead of print)

https://pubmed.ncbi.nlm.nih.gov/32025734

123. Anaya JM, Rojas-Villarraga A... Sarmiento-Monroy JC.  Polyautoimmunity in Sjogren Syndrome.  Rheum Dis Clin North Am 2016; 42 (3):457-472.

https://pubmed.ncbi.nlm.nih.gov/27431348

124. Pego-Reigosa JM, Restrepo Velez J, et al. Comorbidities (excluding lymphoma) in Sjogren's Syndrome.  [published online ahead of print, 2019 Feb 15]. Rheumatology (Oxford). 2019;key329.

https://pubmed.ncbi.nlm.nih.gov/30770715/

125. Chang CC, Chang YS, Wang SH, Lin SY, Chen YH, Chen JH. Primary Sjogren's syndrome and the risk of acute pancreatitis: a nationwide cohort study. BMJ Open. 2017;7(8):e014807. Published 2017 Aug 11. doi:10.1136/bmjopen-2016-014807   https://pubmed.ncbi.nlm.nih.gov/28801391/
 

126. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42(9):968-978. https://pubmed.ncbi.nlm.nih.gov/22827853/

127. Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018;85(6):459-467. https://pubmed.ncbi.nlm.nih.gov/29883308/

 

128. Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, et al. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry [published online ahead of print, 2019 Dec 6]. Rheumatology (Oxford). 2019;kez562. https://pubmed.ncbi.nlm.nih.gov/31808534/

 

129. Fox RI, Fox CM, Gottenberg JE, Dörner T. Treatment of Sjögren's syndrome: current therapy and future directions [published online ahead of print, 2019 Apr 26]. Rheumatology (Oxford). 2019;kez142. doi:10.1093/rheumatology/kez142

https://pubmed.ncbi.nlm.nih.gov/31034046/

 

130,  Wang SQ, Zhang LW, Wei P, Hua H. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017;18(1):186. Published 2017 May 12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427554/  (Open access)

131. Valim V, Trevisani VF, Pasoto SG, et al. Recommendations for the treatment of Sjögren's syndrome. Rev Bras Reumatol. 2015;55(5):446-457.

 https://pubmed.ncbi.nlm.nih.gov/26360421/

132  Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi:10.1136/annrheumdis-2019-216114

https://ard.bmj.com/content/annrheumdis/79/1/3.full.pdf

 

133  Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC. Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. QJM. 2019;112(10):757-762. doi:10.1093/qjmed/hcz112

https://pubmed.ncbi.nlm.nih.gov/31218368/

 

134. Both T, Zillikens MC, Schreuders-Koedam M, et al. Hydroxychloroquine affects bone resorption both in vitro and in vivo. J Cell Physiol. 2018;233(2):1424-1433. doi:10.1002/jcp.26028

https://pubmed.ncbi.nlm.nih.gov/28556961/

 

135. Liu D, Li X, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:1685-1695.

 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001837/    (Open access)

 

136. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249-258.

https://pubmed.ncbi.nlm.nih.gov/25027140/

137. Tarn JR, Howard-Tripp…Gottenberg JE. Symptom-based stratification of patients with primary Sjogren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomized clinical trials.  Lancet Rheumatol 2019; 1: e85-94.

https://www.thelancet.com/action/showPdf?pii=S2665-9913%2819%2930042-6  (Open Access)

138. Jaskólska M, Chylińska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjögren's syndrome: a preliminary report. Rheumatol Int. 2020;40(8):1267-1274. doi:10.1007/s00296-020-04543-2  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316843/    (Open Access)

139.  Yazisiz V, Aslan B, Erbasan F, Uçar İ, Öğüt TS, Terzioğlu ME. Clinical and serological characteristics of seronegative primary Sjögren's syndrome: a comparative study [published online ahead of print, 2020 Jun 5]. Clin Rheumatol. 2020;10.1007/s10067-020-05154-9.

https://pubmed.ncbi.nlm.nih.gov/32504193/

 

140. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. doi:10.1016/j.ophtha.2016.01.058

https://pubmed.ncbi.nlm.nih.gov//26992838/

https://ontariorheum.ca/images/uploads/content_documents/OPHTHA_2011_MarmorMarmor2011dj_AAO_plaquenil.pdf        (Open Access)

 

141.  Narváez, J., Sánchez-Fernández, S. Á., Seoane-Mato, D., Díaz-González, F., & Bustabad, S. (2020). Prevalence of Sjögren's syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Scientific reports, 10(1), 10627. https://doi.org/10.1038/s41598-020-67462-z

https://pubmed.ncbi.nlm.nih.gov//32606345/

142. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31(6):828-845. doi:10.1038/eye.2016.298

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518824/  (Open Access)

143.  Thomas, D. E., Lyons, J. S., Greene, B. S., & Petri, M. A. (2019). Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus science & medicine, 6(1), e000335.

https://doi.org/10.1136/lupus-2019-000335  (Open Access)

144. Dos Reis Neto, E. T., Kakehasi, A. M., de Medeiros Pinheiro, M., Ferreira, G. A., Marques, C., da Mota, L., Dos Santos Paiva, E., Pileggi, G., Sato, E. I., Reis, A., Xavier, R. M., & Provenza, J. R. (2020). Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England), 60(1), 32. https://doi.org/10.1186/s42358-020-00134-8

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202/pdf/42358_2020_Article_134.pdf

145.  Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210-219. doi:10.1097/MD.0b013e318181e6af

https://pubmed.ncbi.nlm.nih.gov/18626304/    (Open Access)

 

146.  Dai, F., Yang, G., Rao, P., Wu, P., Chen, R., Sun, Y., Peng, Y., Qian, H., Wang, B., Chen, S., Liu, Y., & Shi, G. (2020). Clinical Characteristics of Secondary Immune Thrombocytopenia Associated With Primary Sjögren's Syndrome. Frontiers in medicine, 7, 138. https://doi.org/10.3389/fmed.2020.00138

https://pubmed.ncbi.nlm.nih.gov//32363196/   (Open Access)

 

147.  Gyöngyösi, M., Pokorny, G., Jambrik, Z., Kovács, L., Kovács, A., Makula, E., & Csanády, M. (1996). Cardiac manifestations in primary Sjögren's syndrome. Annals of the rheumatic diseases, 55(7), 450–454. https://doi.org/10.1136/ard.55.7.450

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1010208/

148.Mandl,T., Ekberg, O., Wollmer, P., Manthorpe, R., & Jacobsson, L. T. (2007). Dysphagia and dysmotility of the pharynx and oesophagus in patients with primary Sjögren's syndrome. Scandinavian journal of rheumatology, 36(5), 394–401. https://doi.org/10.1080/03009740701607638

https://pubmed.ncbi.nlm.nih.gov/17963171/

149. Levine T. D. (2018). Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning. Journal of central nervous system disease, 10, 1179573518771703. https://doi.org/10.1177/1179573518771703

https://pubmed.ncbi.nlm.nih.gov/29706768/

150.  Heus, A., Arends, S., Van Nimwegen, J. F., Stel, A. J., Nossent, G. D., & Bootsma, H. (2020). Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI. Scandinavian journal of rheumatology, 49(1), 38–46. https://doi.org/10.1080/03009742.2019.1634221

https://pubmed.ncbi.nlm.nih.gov/31556344/

 

151. Vivino F. (2020) Sjogren’s Syndrome: A Clinical Handbook. Amsterdam: Elsevier.

 

152. Larssen, E., Brede, C., Hjelle, A., Tjensvoll, A. B., Norheim, K. B., Bårdsen, K., Jonsdottir, K., Ruoff, P., Omdal, R., & Nilsen, M. M. (2019). Fatigue in primary Sjögren's syndrome: A proteomic pilot study of cerebrospinal fluid. SAGE open medicine, 7, 2050312119850390. https://doi.org/10.1177/2050312119850390

https://pubmed.ncbi.nlm.nih.gov/31205695/

 

 

153. Parisis D, Chivasso C, Perret J, Shahnawaz Soyfoo M, Delporte C.  Current state of knowledge on primary Sjogren’s syndrome, and autoimmune exocrinopathy.  J. Clin. Med. 2020, 9(7), 2299; https://doi.org/10.3390/jcm9072299

https://www.mdpi.com/2077-0383/9/7/2299/htm  (Open Access)

Epub ahead of print

154. Jain, A., Srinivas, B. H., Emmanuel, D., Jain, V. K., Parameshwaran, S., & Negi, V. S. (2018). Renal involvement in primary Sjogren's syndrome: a prospective cohort study. Rheumatology international, 38(12), 2251–2262. https://doi.org/10.1007/s00296-018-4118-x

https://pubmed.ncbi.nlm.nih.gov/30155666/

 

155. François, H., & Mariette, X. (2016). Renal involvement in primary Sjögren syndrome. Nature reviews. Nephrology, 12(2), 82–93. https://doi.org/10.1038/nrneph.2015.174

https://pubmed.ncbi.nlm.nih.gov/26568188/

156. Mathews, P. M., Robinson, S. A., Gire, A., Baer, A. N., & Akpek, E. K. (2020). Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. PloS one, 15(9), e0239769.  https://doi.org/10.1371/journal.pone.0239769

https://pubmed.ncbi.nlm.nih.gov/32976549/   (Open Access)

157. Servioli, L., Maciel, G., Nannini, C., Crowson, C. S., Matteson, E. L., Cornec, D., & Berti, A. (2019). Association of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort Study. The Journal of rheumatology, 46(7), 727–730. https://doi.org/10.3899/jrheum.180481

https://pubmed.ncbi.nlm.nih.gov/30647188/

158. Nilsson, A. M., Diaz, S., Theander, E., Hesselstrand, R., Piitulainen, E., Ekberg, O., Wollmer, P., & Mandl, T. (2015). Chronic obstructive pulmonary disease is common in never-smoking patients with primary Sjögren syndrome. The Journal of rheumatology, 42(3), 464–471. https://doi.org/10.3899/jrheum.140370

https://pubmed.ncbi.nlm.nih.gov/25593235/

159. Noaiseh, G., & Baer, A. N. (2020). Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach. Best practice & research. Clinical rheumatology, 34(1), 101475. https://doi.org/10.1016/j.berh.2019.101475

https://pubmed.ncbi.nlm.nih.gov/32005417/

 

160. Ramírez Sepúlveda, J. I., Kvarnström, M., Eriksson, P., Mandl, T., Norheim, K. B., Johnsen, S. J., Hammenfors, D., Jonsson, M. V., Skarstein, K., Brun, J. G., DISSECT consortium, Rönnblom, L., Forsblad-d'Elia, H., Magnusson Bucher, S., Baecklund, E., Theander, E., Omdal, R., Jonsson, R., Nordmark, G., & Wahren-Herlenius, M. (2017). Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients. Biology of sex differences, 8(1), 25. https://doi.org/10.1186/s13293-017-0146-6

https://pubmed.ncbi.nlm.nih.gov/28789696/    Open Access

Updated 10-13-20